PRAI (PrivaseaAI) fluctuated 42.2% in 24 hours: Low liquidity trading amplified small price swings
Bitget Pulse2026/05/04 09:10Volatility Overview
In the past 24 hours, PRAI price rebounded from a low of $0.00116 to a high of $0.00165, currently at $0.00165, with a price swing of 42.2%. The 24-hour trading volume is roughly $137,600, and low liquidity makes the price easily influenced by trading activity.
Brief Analysis of the Cause of Fluctuation
- No official announcements, major news, or significant on-chain whale transfers were found in the past 24 hours.
- The volatility mainly stems from market speculation in a low market cap (circulating supply of approximately 312 million) environment with low trading volume. Trading on DEXs (such as BSC PancakeSwap) amplifies price sensitivity.
Market Opinions and Outlook
X platform trading signals indicate a short-term bullish bias, suggesting going long near the $0.001202 support with a target of $0.00144, but emphasizing a bearish turn if it breaks below $0.00111. Community discussions are limited; mainstream forecasts expect a slight increase to $0.00118–$0.00119 in May 2026. Risk warning: low liquidity could result in price pullbacks.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring. For informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
